<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508830</url>
  </required_header>
  <id_info>
    <org_study_id>P0530291</org_study_id>
    <nct_id>NCT03508830</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial</brief_title>
  <official_title>Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial - Liposomal Bupivacaine Versus Standard Bupivacaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center,
      double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic
      efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in
      subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Syringe with Obscuring Over-Wrap</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Daily In-Hospital Use of Opioids</measure>
    <time_frame>24 Hours</time_frame>
    <description>Measured in Oral Morphine Equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Daily In-Hospital Pain Score</measure>
    <time_frame>24 Hours</time_frame>
    <description>Measured 0-10 Visual Analog Scale for Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to First Opioid Use</measure>
    <time_frame>Postoperative Day 0</time_frame>
    <description>Measured in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Ambulation</measure>
    <time_frame>Postoperative Day 0</time_frame>
    <description>Measured in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Complication</measure>
    <time_frame>Index Hospitalization following Surgery until Discharge - Up to 1 Week</time_frame>
    <description>Presence of Atelectasis (requiring bronchoscopy) or Pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Index Hospitalization following Surgery until Discharge - Up to 1 Week</time_frame>
    <description>Measured in Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Prescription at Discharge</measure>
    <time_frame>Day of Discharge - Up to 24 Hours</time_frame>
    <description>Measured in Oral Morphine Equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Use as Outpatient</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Measured in Oral Morphine Equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Costs of Hospital Encounter</measure>
    <time_frame>Index Hospitalization following Surgery until Discharge - Up to 1 Week</time_frame>
    <description>Includes Direct Costs of Surgery and Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: Short-Form-36 Health Survey</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Obtained in the pre and postoperative clinic visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Thoracic Diseases</condition>
  <condition>Postoperative Pain</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Drug will be percutaneously injected into intercostal spaces 3-10 under direct intrathoracic vision at the conclusion of surgery.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Bupivacaine</intervention_name>
    <description>Drug will be percutaneously injected into intercostal spaces 3-10 under direct intrathoracic vision at the conclusion of surgery.</description>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Robotic or Video-Assisted Lung Resection for All Indications

        Exclusion Criteria:

          -  Additional Thoracic Procedures (beyond lung resection and mediastinal lymphadenectomy)

          -  Extra-Thoracic Procedures

          -  Hypersensitivity to Amide Local Analgesia

          -  Cardiac Conduction Abnormalities

          -  Hepatic Dysfunction

          -  Preoperative Neuropathic Pain and/or Preoperative Daily Opioid Usage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Greg J Haro, MD</last_name>
    <phone>415-353-8196</phone>
    <email>greg.haro@ucsf.edu</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Johannes R. Kratz, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery Division of Adult Cardiothoracic Surgery; Van Auken Endowed Chair in Thoracic Oncology; Director, Minimally Invasive and Robotic Thoracic Surgery; Associate Director, Thoracic Surgery Residency Program</investigator_title>
  </responsible_party>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Intercostal Nerve Block</keyword>
  <keyword>Minimally Invasive Thoracic Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Thoracic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

